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Abstract
 Background: Endocannabinoids (ECs) are rapidly acting 
immune-modulatory lipid-signaling molecules that are 
important for adaptation to stressful and aversive situa-
tions. They are known to interact with glucocorticoids 
and other stress-responsive systems. Maladaptation to 
acute or chronic stress represents a major risk factor for 
the development of psychiatric disorders. In the present 
study, we administered stress doses of hydrocortisone in 
a prospective, randomized, placebo-controlled double-
blind study in patients undergoing cardiac surgery (CS) to 
examine the relationship between the use of glucocorti-
coids, plasma EC levels, and the occurrence of early post-
operative cognitive dysfunction (delirium) and of later 
development of depression. 
 Methods: We determined plasma levels of the ECs anand-
amide and 2-arachidonoylglycerol (2-AG) in CS patients 
of the hydrocortisone (n = 56) and the placebo group 
(n = 55) preoperatively, at postoperative day (POD) 1, at 
intensive care unit discharge, and at 6 months after CS 
(n = 68). Postoperative delirium was diagnosed accord-
ing to  Diagnostic and Statistical Manual of the American 
Psychiatric Association IVth Edition (DSM-IV) criteria, and 
depression was determined by validated questionnaires 
and a standardized psychological interview (Structured 
Clinical Interview for  DSM-IV ). 
 Results: Stress doses of hydrocortisone did not affect 
plasma EC levels and the occurrence of delirium or 
depression. However, patients who developed delirium 
on POD 1 had significantly lower preoperative 2-AG levels 
of the neuroprotective EC 2-AG (median values, 3.8 vs. 11.3 
ng/ml;  p  = 0.03). Preoperative 2-AG concentrations were 
predictive of postoperative delirium (sensitivity = 0.70; 
specificity = 0.69; cutoff value = 4.9 ng/ml; receiver oper-
ating characteristic curve area = 0.70; 95% confidence 
interval = 0.54 – 0.85). Patients with depression at 6 months 
after CS (n = 16) had significantly  lower anandamide and 
2-AG levels during the perioperative period. 
 Conclusions: A low perioperative EC response may indi-
cate an increased risk for early cognitive dysfunction and 
long-term depression in patients after CS. Glucocorticoids 
do not seem to influence this relationship. 
 Keywords:  cardiac surgery;  delirium;  depression;  endo-
cannabinoids;  glucocorticoids. 
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 Introduction 
 Dysregulation of the endocannabinoid (EC) system is 
thought to contribute to a diverse number of human dis-
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eases, including atherosclerosis (Mach and Steffens, 
2008), systemic inflammation, obesity and the meta-
bolic syndrome (Cote et al., 2007), arterial hypertension 
(Batkai et al., 2004), heart failure (Fajardo and Bernstein, 
2007; Weis et al., 2009b), psychiatric disorders such 
as anxiety and depression (Gobbi et al., 2005; Hill and 
Gorzalka, 2009), and stress-related chronic pain syn-
dromes (Kaufmann et al., 2008). The EC system is a ubiq-
uitous neurobiological and immune-modulatory system, 
mainly consisting of two endogenous ligands  – ananda-
mide and 2-arachidonoylglycerol (2-AG)  – and two types of 
receptors, that is, the cannabinoid 1 receptor (CB1) and the 
cannabinoid 2 receptor (CB2) (Pertwee, 2008). The ECs are 
not circulating hormones and therefore not bound to pro-
teins but synthesized on demand and rapidly degraded. 
CB1 receptors are mainly expressed in the brain (Pertwee, 
2008) but also in peripheral tissues such as heart (Weis 
et al., 2009b), muscle, liver, and adipose tissue (Begg 
et al., 2001). CB2 receptors are primarily found on immune 
cells (Eisenstein et al., 2007), but also within the central 
nervous system (Onaivi et al., 2006) and the heart (Weis 
et al., 2009b). Because of the ubiquitous distribution of 
CB receptors throughout the brain, animal experiments 
have shown a multitude of central physiological functions 
of ECs, for example, memory processing (Marsicano et al., 
2002; Campolongo et al., 2009; Hauer et al., 2011; Atsak 
et al., 2012), neuroprotection and neuroinflammation (Wolf 
et al., 2008), anxiety (Bortolato et al., 2006; Domschke and 
Zwanzger, 2008), reward (Maldonado et al., 2006), and 
feeding behavior (Vickers and Kennett, 2005). Despite this 
diversity of central function modulation, recent studies 
in animals point to a major role of EC signaling in con-
trolling adaptive processes to aversive situations and in 
regulating and limiting stress reactions (Patel and Hillard, 
2008). Maladaptation to acute or chronic stress represents 
a major risk factor for the development of stress-related 
disorders such as depression, anxiety, and even post-
traumatic stress disorder (Schelling et al., 2003). 
 Whereas early studies mainly pointed out the central 
effects of EC signaling, more recent investigations have 
also demonstrated important peripheral functions of 
ECs. The EC system is activated in obesity and associated 
with cardiometabolic disorders in humans (Sugamura 
et al., 2009). The CB1 receptor blocker rimonabant in obese 
humans has resulted in weight loss and multiple benefi-
cial effects on plasma triglycerides, high-density lipopro-
tein levels, glucose tolerance, and systemic inflammation 
(Pacher, 2009). Impairment of EC signaling by CB1 receptor 
blockade, however, led to a significant increase in the inci-
dence of depression and anxiety, particularly in patients 
exposed to stressful situations (Nissen et al., 2008). As a 
consequence, rimonabant never received approval by the 
US Federal Drug Administration and was withdrawn from 
the European market in 2008. Thus, activation of the EC 
system appears to play an important role in the adaptation 
to stressful situations while simultaneously resulting in an 
increased risk for the development of obesity and cardio-
metabolic disorders associated with systemic inflammation. 
 Cardiac surgery (CS) is frequently performed in 
patients with multiple cardiometabolic risk factors and 
induces a profound proinflammatory response related 
to surgery and cardiopulmonary bypass. CS represents a 
considerable stress exposure (Schelling et al., 2003) and 
carries a substantial risk of psychiatric sequelae such as 
chronic stress reactions (Stoll et al., 2000) or anxiety and 
depression (Burker et al., 1995). 
 Patients with depression show significantly lower 
plasma EC concentration (Hill and Gorzalka, 2009) as 
well as changes in glucocorticoid signaling (Treggiari 
et al., 2009). These findings suggest that alteration of cir-
culating levels of glucocorticoids and ECs might influence 
stress-related outcome parameters. We therefore evalu-
ated whether alterations of EC signaling could be predic-
tive of early cognitive dysfunction and later development 
of depression in CS patients treated with placebo or stress 
doses of hydrocortisone (cortisol). 
 Patients and methods 
 Participating patients 
 We studied a cohort of CS patients in a prospective, randomized, 
double-blinded trial that compared the effects of stress doses of 
hydrocortisone to placebo on several short- and long-term outcome 
parameters. The patients were randomized to either hydrocorti-
sone or placebo treatment, and then followed until 6 months after 
CS. We included patients undergoing CS for coronary artery disease 
or cardiac valve replacement. We excluded individuals if they met 
any of the following criteria: combined surgical procedures, emer-
gency surgery, pregnancy, plasma interleukin-6 (IL-6) levels higher 
than 10 pg/ml preoperatively, hepatic dysfunction (bilirubin 
> 3 mg/dl), renal dysfunction (plasma creatinine > 2 mg/dl), a positive 
serological test result for HIV or hepatitis, manifest insulin-depend-
ent diabetes mellitus, use of steroidal or nonsteroidal antiphlogistics 
(except low-dose aspirin) during the last 7 days before surgery, an 
extracardial septic focus, chronic or acute inflammatory disease, and 
an inability to give informed consent. In addition, patients with pre-
vious intensive care unit (ICU) treatment (with the exception of brief 
stays in coronary care units) and those who required glucocorticoids 
for medical reasons (e.g., asthma or rheumatism) were excluded. 
 We screened 535 patients of whom 424 were not eligible for 
randomization on the basis of the above-mentioned exclusion and 
inclusion criteria. Of the 111 patients randomized, three died peri-
operatively in the ICU and 40 were lost to follow-up because of early 
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postoperative transfer to other ICUs away from the study center 
(n = 11) or because they could not be contacted after discharge from 
the hospital (n = 29). The final study population evaluated at the first 
time point (ICU discharge) consisted of 97 patients (87.4% of those 
originally randomized). Of these 97 patients, 68 (70.1%) were available 
for assessment at 6 months after CS. Of these 68 patients, 32 had 
received placebo and 36 had received hydrocortisone. 
 All patients received a detailed explanation of the purpose of 
the study and were able to give informed consent. The study was 
approved by the Institutional Review Board of the Ludwig-Maximil-
ians University of Munich (protocol number 149/00, Amendment) 
and the relevant government and regulatory agencies. Data protec-
tion met the standard set by German law. 
 Sequence of actions during the perioperative 
period and follow-up 
 Patients were evaluated at five time points [1 day before CS, post-
operatively on admittance to the ICU, on postoperative day 1 (POD 
1), at discharge from the ICU, and at 6 months after surgery]. The 
sequence of actions during the study is depicted in  Figure 1 . 
 Study intervention 
 The study drug hydrocortisone (Hydrocortisone-21-hydrogensuc-
cinate, Pharmacia, Berlin, Germany) was administered by using a 
 Figure 1   Flow chart depicting the sequence of actions during the study.
POD 1, postoperative day 1; SCID-IV, Structured Clinical Interview 
for Diagnostic and Statistical Manual of the American Psychiatric 
Association IVth Edition. 
loading dose (100 mg over 10 min, intravenous [IV]) before induction 
of anesthesia, followed by a continuous infusion of 10 mg/h for 24 h 
(POD 1), which was reduced to 5 mg/h on POD 2, and then tapered to 
3  ×  20 mg IV on POD 3, and 3  ×  10 mg IV on POD 4 (Kilger et al., 2003; 
Weis et al., 2009a). 
 Primary and secondary outcome measures 
 The primary outcome parameters of this part of the study were the 
occurrence of delirium and the incidence and intensity of depression 
at 6 months after CS in relation to EC plasma concentrations and the 
use of hydrocortisone. 
 Randomization generation and 
allocation concealment 
 Randomization to hydrocortisone or placebo treatment was per-
formed in blocks of four by using a computer-generated randomiza-
tion list. Patients, investigator staff, persons performing the assess-
ments, and data analysts remained blinded to the identity of the 
treatment from the time of randomization until database lock when 
data entry was finished. 
 Biological and clinical measurements 
 EC levels in human blood 
 Plasma levels of anandamide and 2-AG were determined with high-
performance liquid chromatography-tandem mass spectrometry as 
described elsewhere (Vogeser et al., 2006; Weis et al., 2010). 
 For EC measurements, 4.5 ml of arterial blood was with-
drawn from a cannula placed into the femoral artery. Blood was 
sampled into ethylenediaminetetraacetic acid-containing tubes 
(S-Monovette, Sarstedt, Numbrecht, Germany) and immediately 
(within 5 min) centrifuged at 5000  g over 5 min at 4 ° C and stored. 
The time interval between blood sampling and centrifugation was 
minimized because previous experiments have shown that EC 
generation in blood samples is continued  ex vivo (Schmidt et al., 
2006; Vogeser et al., 2006). Thus, delays in blood processing could 
result in false-positive increases in plasma EC concentrations. 
After centrifugation, the supernatant was immediately aspirated, 
transferred into 1-ml plastic vials, and stored at -80°C until meas-
urement. 
 In biological matrices, 2-AG (including its deuterated analog) 
is rapidly isomerized (Vogeser and Schelling, 2007; Di Marzo et al., 
2009). We therefore quantified 2-AG as the sum of 2-AG and 1-AG and 
refer to the sum of both compounds as 2-AG throughout the paper 
although this basically represents a chemical misnomer. 
 Clinical measurements 
 The clinical and demographic variables measured are depicted in 
 Tables 1 and  2 . 
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 Psychometric measurements 
 Depression 
 The German version of the Hamilton Depression Rating Scale 
(HDRS) was used as a continuous outcome measure for depression 
(Hamilton, 1960) and was administered during the 6-month follow-
up evaluation. As an additional measure of depression, we asked the 
patients to rate their answers to the question  ‘ I feel depressed/down-
trodden ’ on a rating scale ranging from 1 (never) to 7 (always). The 
depression rating scale was administered at the preoperative time 
points and at 6 months after surgery ( Figure 1 ). 
 Diagnosis of early, acute cognitive dysfunction 
and delirium 
 Acute postoperative cognitive dysfunction (ACD) was defined as an 
inadequate neurological response in an awake patient at the first 
attempt of postoperative extubation requiring resedation and pro-
Hydrocortisone (n = 56) Placebo (n = 55) p-Value
Duration of extracorporeal circulationa (min) 114.0±58 107.3±57 0.54
Length of postoperative stay in the ICUa,b (h) 38.3±31.7 68.4±49.9  < 0.01c
Postoperative hsCRPd values (mg/dl) 4.8±0.3 6.0±0.4  < 0.01c
Duration of postoperative mechanical ventilationa (h) 17.1±12.0 21.0±17.0 0.42
Duration of epinephrine therapya (h) 14.1±22.1 16.6±28.8 0.64
 Table 2   Perioperative variables in the placebo group and the hydrocortisone group. 
 a Values are mean ± SD. 
 b Indicates significant differences ( p  < 0.05) between males and females. 
 c Significantly lower values in patients from the hydrocortisone group ( t -test). 
 d Highly sensitive c-reactive protein. 
Baseline variables Hydrocortisone (n = 56) Placebo (n = 55) p-Value
Age (year)a,b 69.3±8.9 68.0±8.3 0.94
Body mass index (BMI)a 28.0±6.4 26.9±5.3 0.37
Sex (male/female) 45/11 47/9 1.00
Preoperative beta-blocker use (n) 34 35 0.65
Diabetes mellitus type II (n)b 11 12 0.57
Coronary artery disease (n) 25 35 0.21
ASA Scorea,b,c 3.1±0.3 3.0±0.0 0.11
NYHA Scorea,d 2.5±0.5 2.2±1.5 0.65
CCS Scorea,e 2.8±0.4 2.3±1.5 0.42
Preoperative hsCRPf values (mg/dl) 0.76±1.41 0.48±0.56 0.20
Preoperative anandamide concentration (ng/ml)a 0.38± 0.11 0.36±0.15 0.51
Preoperative 2-AG concentration (ng/ml)a 27.9±46.7 27.3±57.8 0.96
 Table 1   Comparison of preoperative baseline variables between the hydrocortisone and placebo groups. 
 a Values are mean ± SD. 
 b Indicates significant differences ( p  < 0.05) between males and females. 
 c American Society of Anesthesiologists classification of perioperative risk. 
 d New York Heart Association classification of heart failure. 
 e Canadian Cardiovascular Society classification of angina pectoris. 
 f Denotes highly sensitive C-reactive protein. 
longed ventilation. In extubated patients, delirium was diagnosed 
according to the  Diagnostic and Statistical Manual of the American 
Psychiatric Association IVth Edition ( DSM-IV ) criteria. Patients were 
evaluated for ACD/delirium on POD 1 ( Figure 1 ). 
 Psychiatric interview 
 At approximately 6 months after CS, the patients received a follow-up 
phone call from study personnel and, after repeated oral consent to 
participate in the investigations, were invited to our study center for 
an evaluation of their general health and a psychological interview. 
During the interview, a psychologist (M.S.) performed a thorough 
psychological assessment by using a modified Structured Clinical 
Interview for  DSM-IV (SCID-IV) technique focusing on anxiety disor-
ders and depression ( Figure 1 ). 
 Statistics 
 All variables were tested for normal distribution using the Lilieforts 
Modification of the Kolmogorov-Smirnov test. Normally distributed 
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continuous variables between the two groups were analyzed with 
 t -tests; nonparametric continuous data were analyzed with Mann-
Whitney  U -tests. For discrete variables, the  χ 2 -test or Fisher ’ s exact 
test, when appropriate, was applied. Changes in parameters (e.g., 
EC concentrations) across the five time points of measurement were 
analyzed with a repeated-measurement general linear model (RM-
analysis of variance) with time point as a within-subject variable and 
group assignment as a between-subject variable. 
 The predictive value and optimal cutoff threshold of preopera-
tive EC plasma concentrations for the postoperative development of 
ACD/delirium was quantified by receiver operating characteristic 
(ROC) curve analyses. 
 A  p- value of  < 0.05 was considered statistically significant. 
Statistical analyses were by intention-to-treat by using the  ‘ as rand-
omized as analyzed principle ’ . Data are presented as mean ± SD when 
normally distributed with the exception of figures, where mean ± SEM 
is used to increase clarity. Nonparametric data are presented as 
median and range. All statistical calculations were performed by 
using PASW 18.0 (IBM SPSS Statistics, Chicago, IL, USA). 
 Results
 Clinical parameters 
 Preoperative baseline values, including highly sensitive 
C-reactive protein (hsCRP) values, did not differ signifi-
cantly between patients from the hydrocortisone group 
and the patients from the placebo group ( Tables 1 and 
2 ). Patients from the hydrocortisone group had a signifi-
cantly shorter postoperative stay in the ICU and signifi-
cantly lower postoperative hsCRP values than did patients 
receiving placebo ( Table 2 ), without any other significant 
differences in early clinical outcome parameters. 
 Hydrocortisone and EC plasma 
concentrations 
 The use of hydrocortisone had no significant effect on 
EC plasma concentrations throughout the perioperative 
period ( Figure 2 A and B). 
 EC plasma concentrations changed, however, signifi-
cantly during the perioperative period. Immediately after 
CS, when the patients were deeply sedated and admitted to 
the ICU for postoperative care, anandamide plasma levels 
were significantly lower than preoperatively (0.22 ± 0.13 
vs. 0.38 ± 0.13 ng/ml;  p  < 0.01).a 2-AG concentrations at 
this time point were significantly higher than before 
surgery (46.7 ± 44.4 vs. 32.3 ± 60.7 ng/ml;  p  < 0.01)b and also 
a To convert ng/ml of anandamide into pmol/ml, multiply by 2.88. 
b To convert ng/ml of 2-AG into pmol/ml, multiply by 2.64.
significantly higher than at 6 months after surgery 
(11.0 ± 12.4 ng/ml;  p  < 0.01). At POD1 and at discharge from 
the ICU, anandamide levels were still lower than preop-
eratively but the difference from the baseline values was 
not statistically significant. At these two time points, 2-AG 
levels in patients from the placebo group declined to base-
line (preoperative) values. In the hydrocortisone group, 
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 Figure 2  Stress doses of hydrocortisone and plasma EC levels 
during the perioperative period and 6 months thereafter in patients 
undergoing cardiac surgery. 
There was a significant within-subject effect of time point on 
anandamide ( Figure 2 A, type III sum of squares = 0.267;  F  = 4.04; 
 p  < 0.01) and 2-AG plasma concentrations ( Figure 2 B, type III sum 
of squares = 11978.90;  F  = 4.56;  p  < 0.01), no interaction between 
group assignment and anandamide (type III sum of squares = 0.058; 
 F  = 0.851;  p  = 0.496) and 2-AG concentrations (type III sum of 
squares = 5572.2;  F  = 2.12;  p  = 0.083), and no between-group 
effect of hydrocortisone (type III sum of squares = 0.064;  F  = 2.853; 
 p  = 0.102 for anandamide, and type III sum of squares = 131.06; 
 F  = 0.080;  p  = 0.779 for 2-AG). Data are mean ± SEM. EC, endocan-
nabinoid; RM-ANOVA, repeated-measurement analysis of vari-
ance; 2-AG, 2-arachidonoylglycerol. *Indicates significantly lower 
postoperative anandamide plasma concentrations compared with 
preoperative baseline values (RM-ANOVA with Holm-Sidak post hoc 
test;  p  < 0.01). #Significantly higher postoperative 2-AG concentra-
tions compared with baseline values and with plasma concentra-
tions 6 months after surgery ( p  < 0.01).
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2-AG plasma concentrations showed a more pronounced 
decline but the difference from the placebo group was not 
statistically significant ( Figure 2 A and B). 
Acute cognitive dysfunction and delirium 
 Thirteen patients developed ACD/delirium during ICU 
treatment. The occurrence of delirium was not signifi-
cantly associated with any of the major study end points, 
including postoperative EC levels or the occurrence of 
depression. Patients with ACD/delirium had higher post-
operative proinflammatory IL-6 levels on POD 1 than did 
patients without acute brain dysfunction (median values, 
2378 vs. 81 pg/ml;  p  = 0.002). Patients who developed 
postoperative ACD/delirium had significantly lower pre-
operative 2-AG levels (median values, 3.8 vs. 11.3, ng/ml; 
 p  = 0.032) and significantly higher hsCRP values (1.5 vs. 0.53 
 μ g/ml;  p  = 0.004). Low preoperative 2-AG levels were predic-
tive for postoperative ACD/delirium (ROC curve area = 0.70; 
95% confidence interval [CI] = 0.54 – 0.85;  Figure 3 ), whereas 
hsCRP was not (ROC curve area = 0.34; 95% CI = 0.14 – 0.54). 
Patients with delirium showed a trend toward a longer 
stay in the ICU ( p  = 0.070). The use of hydrocortisone had 
no effect on the incidence of ACD/delirium (six patients 
from the placebo group developed ACD/delirium vs. seven 
patients from the hydrocortisone group;  p  = 0.771). 
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 Figure 3  ROC curve analysis showing sensitivity and specific-
ity of preoperative plasma 2-AG concentrations as a predictor of 
postoperative ACD/delirium on POD 1. ACD, acute postoperative 
cognitive dysfunction; ROC, receiver operating characteristic; POD1, 
postoperative day 1; 2-AG, 2-arachidonoylglycerol. 
 Glucocorticoids and depression 
 At 6 months after CS, patients from the hydrocortisone 
group had significantly lower HDRS depression scores 
than did those from the placebo group [median values, 2 
(0 – 5) vs. 6 (1 – 9);  p  = 0.03]. This finding could, however, not 
been confirmed by the psychological interview. According 
to SCID-IV, 5 out of 36 patients (13.8%) from the hydrocor-
tisone group and 11 out of 32 patients (34.4%) from the 
placebo group had evidence of depression, but this differ-
ence did not reach significance ( p  = 0.160). 
 The 16 patients diagnosed with depression had sig-
nificantly higher scores on the depression rating scale at 
6 months after CS (2.8 ± 3.0 vs. 1.1 ± 0.25;  p  = 0.003), without 
significant differences at the preoperative time point 
(2.0 ± 1.1 vs. 1.8 ± 1.2;  p  = 0.550), indicating new onset of 
depression after CS. 
 EC plasma concentrations and emotional 
outcomes 
 When compared with patients without depression, 
patients with evidence of depression at 6 months after CS 
had significantly  lower anandamide plasma levels during 
the immediate postoperative period ( p  = 0.002) ( Figure 4 A). 
The perioperative 2-AG response in patients with depres-
sion was significantly  lower than in mentally healthy indi-
viduals who showed significantly  increased 2-AG levels 
throughout the entire postoperative period ( Figure 4 B). 
 Discussion 
 This study investigated the relationship between changes 
in the peripheral EC system and emotional as well as 
early neurocognitive outcomes in patients treated with 
placebo or stress doses of hydrocorticosterone and under-
going highly stressful CS. Whereas hydrocortisone had 
no direct effects on plasma ECs, early cognitive dysfunc-
tion, or depression, patients with a lower perioperative 
EC response were at an increased risk for both types of 
adverse outcomes. 
 It has been suggested that EC signaling is required 
for stress adaptation and that a dysfunction of the EC 
system or an inability to upregulate its activity during 
stressful conditions could predispose individuals to the 
development of depression or other stress-related disor-
ders (Gorzalka et al., 2008; Patel and Hillard, 2008; Hill 
et al., 2009, 2010; Moreira et al., 2009; Atsak et al., 2012). 
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 Figure 4  Changes in anandamide and 2-AG plasma concentrations 
across the study period in patients with depression and in patients 
without symptoms of depression at 6 months after CS. 
 Data are mean ± SEM. Panel (A) shows anandamide plasma concen-
trations. There was a strong trend toward a between-group effect 
for depression on anandamide levels (type III sum of squares = 0.27; 
 F  = 4.1; RM-ANOVA; p  = 0.05). CS, cardiac surgery; RM-ANOVA, 
repeated-measurement analysis of variance; 2-AG, 2-arachidonoyl-
glycerol. *Indicates significantly higher postoperative anandamide 
concentrations in patients who did not show evidence of later 
depression ( p  < 0.01). Panel (B) shows 2-AG plasma concentrations. 
RM-ANOVA revealed a significant between-group effect of depres-
sion (type III sum of squares = 8967.8;  F  = 6.9;  p  = 0.02). *Indicates 
significantly higher postoperative 2-AG levels in patients without 
depression at 6 months after CS ( p  < 0.01). 
At least two recent studies reported reduced plasma levels 
of anandamide or 2-AG in patients with depression (Hill et 
al., 2008, 2009). Moreover, patients from four large studies 
who received the CB1 receptor blocker rimonabant for 
treatment of obesity and cardiometabolic disorders were 
2.5 times more likely to drop out from the study because of 
depression and depressive symptoms than those who took 
placebo, and 3 times more likely to discontinue treatment 
because of anxiety (Mitchell and Morris, 2007). Consistent 
with these findings, patients from our study who developed 
new-onset depression or depressive-like symptoms after 
CS had significantly lower plasma anandamide and 2-AG 
concentrations during the highly stressful perioperative 
period. Interestingly, a similar EC response pattern was 
found in severely stressed participants of a recent para-
bolic flight experiment who developed acute motion sick-
ness. In contrast, volunteers who tolerated the experi-
ment well and were only minimally stressed showed a 
significant increase in plasma ECs throughout the para-
bolic flight maneuvers (Chouker et al., 2010). 
 Interestingly, we have previously shown that loss of 
consciousness in our CS patients as a result of general 
anesthesia with a benzodiazepine and a volatile agent 
(isoflurane) led to a significant decline in plasma anan-
damide concentrations (Weis et al., 2010). Anandamide 
levels remained low during postoperative sedation with 
midazolam in the ICU. When patients regained con-
sciousness after surgery in the ICU, anandamide levels 
returned to baseline. Comparable effects were seen in 
patients anesthetized with the volatile agent sevoflu-
rane undergoing orthopedic surgery. In contrast, in 
patients from the same study who were anesthetized 
with the intravenous agent propofol, a known inhibi-
tor of the anandamide degradation enzyme fatty acid 
amide hydrolase, anandamide blood concentrations 
were maintained and no significant reduction was seen 
during general anesthesia and surgery (Schelling et al., 
2006). We have recently shown that administration of 
anesthetic doses of propofol shortly after an aversive 
learning experience elevated brain anandamide content 
and strengthened memory formation of the learning 
experience in rats (Hauer et al., 2011). These effects 
were not seen with midazolam. As the development 
of traumatic memories after a stressful situation is an 
important risk factor for the occurrence of anxiety and 
other stress-related disorders (Schelling et al., 2003; 
Kapfhammer et al., 2004), these findings suggest that 
the choice of sedative agents in the ICU might contribute 
to the neuroemotional outcome of CS (Hemmings and 
Mackie, 2011). 
 An interesting finding of the present study is the rela-
tionship between low preoperative 2-AG levels and the 
later development of ACD/delirium. Although there is 
currently no unequivocal biological explanation for this 
observation, there is clear evidence that ECs are mark-
edly increased in response to pathogenic events in the 
brain (Shohami et al., 2011). Numerous experimental 
studies on models of brain toxicity, neuroinflammation, 
and trauma support the notion that ECs are part of the 
brain ’ s compensatory or repair mechanisms (Shohami 
et al., 2011). 2-AG is known to regulate neurotransmission 
and neuroinflammation by activating CB1 receptors on 
neurons and CB2 receptors and abnormal cannabidiol-
sensitive receptors on microglia in the brain, suggesting a 
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possible neuroprotective effect of 2-AG (Kreutz et al., 
2009; Lourbopoulos et al., 2011). Patients with an inad-
equately low perioperative 2-AG response might be at risk 
for early postoperative ACD/delirium  and for the later 
development of depression. A significant association 
between depression and delirium has been demonstrated 
in CS patients (Ronksley et al., 2011). 
 The present study has some technical limitations. The 
clinical nature of our study limited our study to investiga-
tions of peripheral EC activity, which may not necessar-
ily reflect central EC signaling. Preclinical findings show, 
however, that elements of the peripheral EC system may 
mirror central dysfunctions of EC signaling (Centonze 
et al., 2008). There is, indeed, evidence that EC activity in 
peripheral nucleated blood cells is related to changes in 
central EC signaling, which could theoretically allow the 
use of peripheral EC measurements as a diagnostic tool for 
a number of neuropsychiatric disorders (Centonze et al., 
2008). In addition, the stress associated with footshock 
administration to rats resulted in an almost simultane-
ous increase in anandamide concentrations in blood and 
several memory-related brain areas including the amyg-
dala and hippocampus (Hauer et al., in preparation). 
 A further limitation of our study results from the fact 
that the number of patients available for the 6-month 
follow-up was considerably smaller than the number 
of patients initially randomized. Despite our intention-
to-treat approach for data analyses, this could have led to 
a substantial degree of selection bias (e.g., patients with 
a less favorable outcome or a higher degree of depression 
could have avoided traveling to the study center). Fur-
thermore, psychological interviews could be performed 
only at the 6-month follow-up. Thus, some patients could 
have had preexisting depression at study inclusion, which 
is common in patients undergoing CS (Stroobant and 
Vingerhoets, 2008). However, as we found no significant 
difference in depression self-rating scores at the preop-
erative time point between patients who had evidence of 
depression at 6 months after CS and those who did not, 
the findings suggest new onset of depression after CS. 
 In summary, a more pronounced perioperative EC 
response, independently of glucocorticoid treatment, 
appears to be protective with regard to the development of 
ACD and depression in severely stressed patients undergo-
ing CS. 
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ported this study. 
Clinical Trial Registration Information: NCT00490828 
(http://clinicaltrials.gov/). 
 Received April 28, 2012; accepted August 1, 2012; previously 
published online September 24, 2012
 References 
 Atsak, P., Hauer, D., Campolongo, P., Schelling, G., McGaugh, J.L., 
and Roozendaal, B. (2012). Glucocorticoids interact with the 
hippocamapal endocannabinoid system in impairing retrieval 
of contextual fear memory. Proc. Natl. Acad. Sci. USA 109 , 
3504 – 3509. 
 Batkai, S., Pacher, P., Osei-Hyiaman, D., Radaeva, S., Liu, J., Harvey-
White, J., Offertaler, L., Mackie, K., Rudd, M.A., Bukoski, 
R.D., et al. (2004). Endocannabinoids acting at cannabinoid-1 
receptors regulate cardiovascular function in hypertension. 
Circulation 110 , 1996 – 2002. 
 Begg, M., Baydoun, A., Parsons, M.E., and Molleman, A. (2001). 
Signal transduction of cannabinoid CB1 receptors in a smooth 
muscle cell line. J. Physiol. 531 , 95 – 104. 
 Bortolato, M., Campolongo, P., Mangieri, R.A., Scattoni, M.L., Frau, R., 
Trezza, V., La Rana, G., Russo, R., Calignano, A., Gessa, G.L., et 
al. (2006). Anxiolytic-like properties of the anandamide transport 
inhibitor AM404. Neuropsychopharmacology 31 , 2652 – 2659. 
 Burker, E.J., Blumenthal, J.A., Feldman, M., Burnett, R., White, W., 
Smith, L.R., Croughwell, N., Schell, R., Newman, M., and Reves, 
J.G. (1995). Depression in male and female patients undergoing 
cardiac surgery. Br. J. Clin. Psychol. 34 (Pt 1), 119 – 128. 
 Campolongo, P., Roozendaal, B., Trezza, V., Hauer, D., Schelling, G., 
McGaugh, J.L., and Cuomo, V. (2009). Endocannabinoids in the 
rat basolateral amygdala enhance memory consolidation and 
enable glucocorticoid modulation of memory. Proc. Natl. Acad. 
Sci. USA 106 , 4888 – 4893. 
 Centonze, D., Battistini, L., and Maccarrone, M. (2008). The 
endocannabinoid system in peripheral lymphocytes as a 
mirror of neuroinflammatory diseases. Curr. Pharm. Des. 14 , 
2370 – 2342. 
 Chouker, A., Kaufmann, I., Kreth, S., Hauer, D., Feuerecker, M., 
Thieme, D., Vogeser, M., Thiel, M., and Schelling, G. (2010). 
Motion sickness, stress and the endocannabinoid system. 
PLoS One 5 , e10752. 
 Cote, M., Matias, I., Lemieux, I., Petrosino, S., Almeras, N., Despres, 
J.P., and Di Marzo, V. (2007). Circulating endocannabinoid 
levels, abdominal adiposity and related cardiometabolic risk 
factors in obese men. Int. J. Obes. (Lond.) 31 , 692 – 699. 
 Di Marzo, V., Verrijken, A., Hakkarainen, A., Petrosino, S., Mertens, 
I., Lundbom, N., Piscitelli, F., Westerbacka, J., Soro-Paavonen, 
A., Matias, I., et al. (2009). Role of insulin as a negative 
regulator of plasma endocannabinoid levels in obese and 
nonobese subjects. Eur. J. Endocrinol. 161 , 715 – 722. 
 Domschke, K. and Zwanzger, P. (2008). GABAergic and endocan-
nabinoid dysfunction in anxiety  – future therapeutic targets? 
Curr. Pharm. Des. 14 , 3508 – 3517. 
 Eisenstein, T.K., Meissler, J.J., Wilson, Q., Gaughan, J.P., and Adler, 
M.W. (2007). Anandamide and Delta9-tetrahydrocannabinol 
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 31.10.13 15:13
 D. Hauer et al.: Endocannabinoids and cardiac surgery   689
directly inhibit cells of the immune system via CB2 receptors. 
J. Neuroimmunol. 189 , 17 – 22. 
 Fajardo, G. and Bernstein, D. (2007). Endocannabinoid inhibition: 
a new cardioprotective strategy against doxorubicin cardio-
toxicity. J. Am. Coll. Cardiol. 50 , 537 – 539. 
 Gobbi, G., Bambico, F.R., Mangieri, R., Bortolato, M., Campolongo, P., 
Solinas, M., Cassano, T., Morgese, M.G., Debonnel, G., Duranti, 
A., et al. (2005). Antidepressant-like activity and modulation of 
brain monoaminergic transmission by blockade of anandamide 
hydrolysis. Proc. Natl. Acad. Sci. USA 102 , 18620 – 18625. 
 Gorzalka, B.B., Hill, M.N., and Hillard, C.J. (2008). Regulation of 
endocannabinoid signaling by stress: implications for stress-
related affective disorders. Neurosci. Biobehav. Rev. 32 , 
1152 – 1160. 
 Hamilton, M. (1960). A rating scale for depression. J. Neurol. 
Neurosurg. Psychiatry 23 , 56 – 62. 
 Hauer, D., Ratano, P., Morena, M., Scaccianoce, S., Briegel, I., 
Palmery, M., Cuomo, V., Roozendaal, B., Schelling, G., and 
Campolongo, P. (2011). Propofol enhances memory formation 
via an interaction with the endocannabinoid system. 
Anesthesiology 114 , 1380 – 1388. 
 Hemmings, H.C., Jr. and Mackie, K. (2011). The rivers of lethe and 
mnemosyne converge: propofol and memory consolidation. 
Anesthesiology 114 , 1277 – 1279. 
 Hill, M.N. and Gorzalka, B.B. (2009). Impairments in endocan-
nabinoid signaling and depressive illness. J. Am. Med. Assoc. 
301 , 1165 – 1166. 
 Hill, M.N., Miller, G.E., Ho, W.S., Gorzalka, B.B., and Hillard, C.J. 
(2008). Serum endocannabinoid content is altered in females 
with depressive disorders: a preliminary report. Pharmacopsy-
chiatry 41 , 48 – 53. 
 Hill, M.N., Miller, G.E., Carrier, E.J., Gorzalka, B.B., and Hillard, 
C.J. (2009). Circulating endocannabinoids and N-acyl ethano-
lamines are differentially regulated in major depression and 
following exposure to social stress. Psychoneuroendocrinology 
34 , 1257 – 1268. 
 Hill, M.N., Patel, S., Campolongo, P., Tasker, J.G., Wotjak, C.T., and 
Bains, J.S. (2010). Functional interactions between stress 
and the endocannabinoid system: from synaptic signaling to 
behavioral output. J. Neurosci. 30 , 14980 – 14986. 
 Kapfhammer, H.P., Rothenhausler, H.B., Krauseneck, T., Stoll, C., 
and Schelling, G. (2004). Posttraumatic stress disorder and 
health-related quality of life in long-term survivors of acute 
respiratory distress syndrome. Am. J. Psychiatry 161 , 45 – 52. 
 Kaufmann, I., Schelling, G., Eisner, C., Richter, H.P., Krauseneck, T., 
Vogeser, M., Hauer, D., Campolongo, P., Chouker, A., Beyer, A., 
et al. (2008). Anandamide and neutrophil function in patients 
with fibromyalgia. Psychoneuroendocrinology 33 , 676 – 685. 
 Kilger, E., Weis, F., Briegel, J., Frey, L., Goetz, A.E., Reuter, D., Nagy, 
A., Schuetz, A., Lamm, P., Knoll, A., et al. (2003). Stress doses of 
hydrocortisone reduce severe systemic inflammatory response 
syndrome and improve early outcome in a risk group of patients 
after cardiac surgery. Crit. Care Med. 31 , 1068 – 1074. 
 Kreutz, S., Koch, M., Bottger, C., Ghadban, C., Korf, H.W., and 
Dehghani, F. (2009). 2-Arachidonoylglycerol elicits neuropro-
tective effects on excitotoxically lesioned dentate gyrus 
granule cells via abnormal-cannabidiol-sensitive receptors on 
microglial cells. Glia 57 , 286 – 294. 
 Lourbopoulos, A., Grigoriadis, N., Lagoudaki, R., Touloumi, 
O., Polyzoidou, E., Mavromatis, I., Tascos, N., Breuer, A., 
Ovadia, H., Karussis, D., et al. (2011). Administration of 
2-arachidonoylglycerol ameliorates both acute and chronic 
experimental autoimmune encephalomyelitis. Brain Res. 1390 , 
126 – 141. 
 Mach, F. and Steffens, S. (2008). The role of the endocannabinoid 
system in atherosclerosis. J. Neuroendocrinol. 20 (Suppl 1), 
53 – 57. 
 Maldonado, R., Valverde, O., and Berrendero, F. (2006). Involvement 
of the endocannabinoid system in drug addiction. Trends 
Neurosci. 29 , 225 – 232. 
 Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., 
Cascio, M.G., Hermann, H., Tang, J., Hofmann, C., Zieglgan-
sberger, W., et al. (2002). The endogenous cannabinoid system 
controls extinction of aversive memories. Nature 418 , 
530 – 534. 
 Mitchell, P.B. and Morris, M.J. (2007). Depression and anxiety with 
rimonabant. Lancet 370 , 1671 – 1672. 
 Moreira, F.A., Grieb, M., and Lutz, B. (2009). Central side-effects 
of therapies based on CB1 cannabinoid receptor agonists and 
antagonists: focus on anxiety and depression. Best Pract. Res. 
Clin. Endocrinol. Metab. 23 , 133 – 144. 
 Nissen, S.E., Nicholls, S.J., Wolski, K., Rodes-Cabau, J., Cannon, C.P., 
Deanfield, J.E., Despres, J.P., Kastelein, J.J., Steinhubl, S.R., 
Kapadia, S., et al. (2008). Effect of rimonabant on progression 
of atherosclerosis in patients with abdominal obesity and 
coronary artery disease: the STRADIVARIUS randomized 
controlled trial. J. Am. Med. Assoc. 299 , 1547 – 1560. 
 Onaivi, E.S., Ishiguro, H., Gong, J.P., Patel, S., Perchuk, A., Meozzi, 
P.A., Myers, L., Mora, Z., Tagliaferro, P., Gardner, E., et al. 
(2006). Discovery of the presence and functional expression of 
cannabinoid CB2 receptors in brain. Ann. NY Acad. Sci. 1074 , 
514 – 536. 
 Pacher, P. (2009). Cannabinoid CB1 receptor antagonists for 
atherosclerosis and cardiometabolic disorders: new hopes, old 
concerns? Arterioscler. Thromb. Vasc. Biol. 29 , 7 – 9. 
 Patel, S. and Hillard, C.J. (2008). Adaptations in endocannabinoid 
signaling in response to repeated homotypic stress: a novel 
mechanism for stress habituation. Eur. J. Neurosci. 27 , 
2821 – 2829. 
 Pertwee, R.G. (2008). Ligands that target cannabinoid receptors in 
the brain: from THC to anandamide and beyond. Addict. Biol. 
13 , 147 – 159. 
 Ronksley, P.E., Brien, S.E., Turner, B.J., Mukamal, K.J., and Ghali, 
W.A. (2011). Association of alcohol consumption with selected 
cardiovascular disease outcomes: a systematic review and 
meta-analysis. Br. Med. J. 342 , d671. 
 Schelling, G., Richter, M., Roozendaal, B., Rothenhausler, H.B., 
Krauseneck, T., Stoll, C., Nollert, G., Schmidt, M., and 
Kapfhammer, H.P. (2003). Exposure to high stress in the 
intensive care unit may have negative effects on health-related 
quality-of-life outcomes after cardiac surgery. Crit. Care Med. 
31 , 1971 – 1980. 
 Schelling, G., Hauer, D., Azad, S.C., Schmoelz, M., Chouker, A., 
Schmidt, M., Hornuss, C., Rippberger, M., Briegel, J., Thiel, 
M., et al. (2006). Effects of general anesthesia on anandamide 
blood levels in humans. Anesthesiology 104 , 273 – 277. 
 Schmidt, A., Brune, K., and Hinz, B. (2006). Determination 
of the endocannabinoid anandamide in human plasma 
by high-performance liquid chromatography. Biomed. 
Chromatogr. 20 , 336 – 342. 
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 31.10.13 15:13
690   D. Hauer et al.: Endocannabinoids and cardiac surgery
 Shohami, E., Cohen-Yeshurun, A., Magid, L., Elgali, M., and 
Mechoulam, R. (2011). Endocannabinoids and traumatic brain 
injury. Br. J. Pharmacol  163 , 1402 – 1410. 
 Stoll, C., Schelling, G., Goetz, A.E., Kilger, E., Bayer, A., 
Kapfhammer, H.P., Rothenhausler, H.B., Kreuzer, E., Reichart, 
B., and Peter, K. (2000). Health-related quality of life and 
post-traumatic stress disorder in patients after cardiac surgery 
and intensive care treatment. J. Thorac. Cardiovasc. Surg. 120 , 
505 – 512. 
 Stroobant, N. and Vingerhoets, G. (2008). Depression, anxiety, and 
neuropsychological performance in coronary artery bypass 
graft patients: a follow-up study. Psychosomatics 49 , 
326 – 331. 
 Sugamura, K., Sugiyama, S., Nozaki, T., Matsuzawa, Y., Izumiya, Y., 
Miyata, K., Nakayama, M., Kaikita, K., Obata, T., Takeya, M., 
et al. (2009). Activated endocannabinoid system in coronary 
artery disease and antiinflammatory effects of cannabinoid 1 
receptor blockade on macrophages. Circulation 119 , 28 – 36. 
 Treggiari, M.M., Romand, J.A., Yanez, N.D., Deem, S.A., Goldberg, 
J., Hudson, L., Heidegger, C.P., and Weiss, N.S. (2009). 
Randomized trial of light versus deep sedation on mental 
health after critical illness. Crit. Care Med. 37 , 2527 – 2534. 
 Vickers, S.P. and Kennett, G.A. (2005). Cannabinoids and the 
regulation of ingestive behaviour. Curr. Drug Targets 
6 , 215 – 223. 
 Vogeser, M. and Schelling, G. (2007). Pitfalls in measuring the 
endocannabinoid 2-arachidonoyl glycerol in biological 
samples. Clin. Chem. Lab. Med. 45 , 1023 – 1025. 
 Vogeser, M., Hauer, D., Christina Azad, S., Huber, E., Storr, M., and 
Schelling, G. (2006). Release of anandamide from blood cells. 
Clin. Chem. Lab. Med. 44 , 488 – 491. 
 Weis, F., Beiras-Fernandez, A., Schelling, G., Briegel, J., Lang, P., 
Hauer, D., Kreth, S., Kaufmann, I., Lamm, P., and Kilger, E. 
(2009a). Stress doses of hydrocortisone in high-risk patients 
undergoing cardiac surgery: effects on interleukin-6 to 
interleukin-10 ratio and early outcome. Crit. Care Med. 37 , 
1685 – 1690. 
 Weis, F., Beiras-Fernandez, A., Sodian, R., Kaczmarek, I., 
Reichart, B., Beiras, A., Schelling, G., and Kreth, S. (2009b). 
Substantially altered expression pattern of cannabinoid 
receptor 2 and activated endocannabinoid system in patients 
with severe heart failure. J. Mol. Cell Cardiol. 48 , 1187 – 1193. 
 Weis, F., Beiras-Fernandez, A., Hauer, D., Hornuss, C., Sodian, 
R., Kreth, S., Briegel, J., and Schelling, G. (2010). Effect of 
anaesthesia and cardiopulmonary bypass on blood endocan-
nabinoid concentrations during cardiac surgery. Br. J. Anaest. 
105 , 139 – 144. 
 Wolf, S.A., Tauber, S., and Ullrich, O. (2008). CNS immune 
surveillance and neuroinflammation: endocannabinoids keep 
control. Curr. Pharm. Des. 14 , 2266 – 2278. 
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 31.10.13 15:13
